TNXP Tonix Pharmaceuticals Holding Corp.

0.46
+0.01  (+2%)
Previous Close 0.45
Open 0.47
Price To Book 0.55
Market Cap 7,061,963
Shares 15,362,112
Volume 69,781
Short Ratio
Av. Daily Volume 404,645
Stock charts supplied by TradingView

NewsSee all news

  1. Tonix Pharmaceuticals Joins the Alliance for Biosecurity

    NEW YORK, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that it has joined the Alliance for

  2. Tonix Pharmaceuticals Announces that the European Patent Office Opposition Division Has Upheld Its Patent for the Use of the Active Ingredient in TNX-102 SL, Cyclobenzaprine, for the Treatment of PTSD

    NEW YORK, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the European Patent Office's (EPO)

  3. Tonix Pharmaceuticals Announces Completion of Long-Term Exposure Studies in Participants with PTSD to Evaluate the Tolerability of TNX-102 SL 5.6 mg

    NEW YORK, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced Tonix has completed collecting the

  4. Tonix Pharmaceuticals Announces Licensing Agreement with Columbia University for the Development of Recombinant Trefoil Family Factor 2 (rTFF2), or TNX-1700, for the Treatment of Gastric and Pancreatic Cancers

    NEW YORK, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that it has obtained an exclusive

  5. Tonix Pharmaceuticals Announces Publication of Paper on Triple Reuptake Inhibitor TNX-1600 (formerly D-578) in the European Journal of Pharmacology

    NEW YORK, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the publication of a paper entitled

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial halted due to insufficient efficacy - July 27, 2018.
TNX-102 SL (Tonmya)
Post-traumatic stress disorder (PTSD)
Phase 2 data released February 2016 did not meet primary endpoint
TNX-201
Episodic tension-type headache
Phase 3 data September 6, 2016 did not meet primary endpoint - program discontinued. However company noted April 4, 2019 intention to initiate a Phase 3 trial.
TNX-102 SL
Fibromyalgia
Phase 3 data due 1H 2020.
Tonmya
Post-traumatic stress disorder (PTSD)
In-licensed - noted May 23, 2019.
TNX-1300 (RBP-8000)
Cocaine intoxication
Phase 1 initiation of dosing announced September 4, 2019 with data due by the end of 2019.
TNX-601
PK trial

Latest News

  1. Tonix Pharmaceuticals Joins the Alliance for Biosecurity

    NEW YORK, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that it has joined the Alliance for

  2. Tonix Pharmaceuticals Announces that the European Patent Office Opposition Division Has Upheld Its Patent for the Use of the Active Ingredient in TNX-102 SL, Cyclobenzaprine, for the Treatment of PTSD

    NEW YORK, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the European Patent Office's (EPO)

  3. Tonix Pharmaceuticals Announces Completion of Long-Term Exposure Studies in Participants with PTSD to Evaluate the Tolerability of TNX-102 SL 5.6 mg

    NEW YORK, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced Tonix has completed collecting the

  4. Tonix Pharmaceuticals Announces Licensing Agreement with Columbia University for the Development of Recombinant Trefoil Family Factor 2 (rTFF2), or TNX-1700, for the Treatment of Gastric and Pancreatic Cancers

    NEW YORK, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that it has obtained an exclusive

  5. Tonix Pharmaceuticals Announces Publication of Paper on Triple Reuptake Inhibitor TNX-1600 (formerly D-578) in the European Journal of Pharmacology

    NEW YORK, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the publication of a paper entitled

  6. Tonix Pharmaceuticals to Speak at the 2019 Annual National Association of Veterans' Research and Education Foundations (NAVREF) Conference

    NEW YORK, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), today announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will

  7. Tonix Pharmaceuticals to Present at Upcoming September Investor Conferences

    NEW YORK, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company) announced today that Company management will present at three upcoming investor conferences.

  8. Tonix Pharmaceuticals Doses Participants in Phase 1 Study Evaluating TNX-601 for the Daytime Treatment of Posttraumatic Stress Disorder

    NEW YORK, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that participants were dosed in a Phase